The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.
Yousuke Nakai
No relevant relationships to disclose
Hiroyuki Isayama
No relevant relationships to disclose
Takashi Sasaki
No relevant relationships to disclose
Kei Saito
No relevant relationships to disclose
Naminatsu Takahara
No relevant relationships to disclose
Suguru Mizuno
No relevant relationships to disclose
Tsuyoshi Hamada
No relevant relationships to disclose
Koji Miyabayashi
No relevant relationships to disclose
Keisuke Yamamoto
No relevant relationships to disclose
Hirofumi Kogure
No relevant relationships to disclose
Natsuyo Yamamoto
No relevant relationships to disclose
Kenji Hirano
No relevant relationships to disclose
Hideaki Ijichi
No relevant relationships to disclose
Keisuke Tateishi
No relevant relationships to disclose
Minoru Tada
No relevant relationships to disclose
Kazuhiko Koike
No relevant relationships to disclose